dalteparin has been researched along with Secondary Hyperparathyroidism in 1 studies
Dalteparin: A low-molecular-weight fragment of heparin, prepared by nitrous acid depolymerization of porcine mucosal heparin. The mean molecular weight is 4000-6000 daltons. It is used therapeutically as an antithrombotic agent. (From Merck Index, 11th ed)
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| van der Voort, PH | 1 |
| Postma, SR | 1 |
| Kingma, WP | 1 |
| Boerma, EC | 1 |
| de Heide, LJ | 1 |
| Bakker, AJ | 1 |
1 trial available for dalteparin and Secondary Hyperparathyroidism
| Article | Year |
|---|---|
An observational study on the effects of nadroparin-based and citrate-based continuous venovenous hemofiltration on calcium metabolism.
Topics: Acute Kidney Injury; Aged; Anticoagulants; Calcium; Calcium Citrate; Chelating Agents; Citrates; Cri | 2007 |